<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286182</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB3037</org_study_id>
    <secondary_id>R01AG027518-01</secondary_id>
    <nct_id>NCT00286182</nct_id>
  </id_info>
  <brief_title>Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)</brief_title>
  <official_title>Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mathew S. Maurer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin
      in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated
      with reverse ventricular remodeling, significant improvements in exercise capacity, and
      improved health status, as compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure frequently occurs in patients with a preserved ejection fraction (HFPEF) and
      affected subjects are predominantly elderly women with several co-morbid conditions. Despite
      the diversity of underlying clinical pathologies and co-morbid conditions present in these
      patients, a common pathophysiologic explanation is generally applied to explain their
      clinical symptoms. Our preliminary data show that a significant subgroup with HFPEF has
      increases in ventricular volumes and expanded plasma volumes, consistent with a volume
      overloaded state. In the setting of a preserved EF with end diastolic volume increased,
      stroke volume must increase, indicating a high output state. Anemia may be an important,
      modifiable contributor to the observed high output and volume overload as well as exercise
      intolerance in elderly HFPEF patients, abnormal ventricular remodeling and impaired overall
      health status and quality of life. This protocol evaluates the impact of treating anemia in
      subjects with HFPEF. The specific aims of the current study are to provide a comprehensive
      and mechanistically based assessment of how correcting anemia in subjects with HFPEF can
      impact on functional capacity, ventricular structure and function and overall health status.
      We propose to perform a randomized, prospective, double blind study in 80 subjects with HFPEF
      to test the hypothesis that the administration of subcutaneous erythropoietin will be
      associated with reverse ventricular remodeling, significant improvements in exercise capacity
      and improved health status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular End-diastolic Volume</measure>
    <time_frame>Baseline and 6 month</time_frame>
    <description>This outcome measure is collected using a three dimensional echocardiography.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Erythropoietin alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo consists of saline injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin alpha</intervention_name>
    <description>Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.</description>
    <arm_group_label>Erythropoietin alpha</arm_group_label>
    <other_name>Erythropoietin alpha (Epogen)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Heart failure and a preserved ejection fraction (HFPEF) - EF &gt;=40%

          2. Anemia - defined as hemoglobin &lt; 12 g/dL

          3. Age &gt;= 55 years

          4. Patients must be able to understand and sign the informed consent document after the
             nature of the study has been fully explained, prior to beginning any study procedures.

        Exclusion Criteria:

          1. Presence of uncontrolled hypertension (Systolic blood pressure &gt; 160 mm Hg and/or
             diastolic blood pressure &gt; 90 mm Hg)

          2. Resting heart rate &gt; 120 bpm

          3. Baseline 6-minute walk test &gt; 450 meters

          4. Valvular heart disease (e.g. more than mild regurgitant or stenotic mitral, aortic,
             tricuspid, or pulmonic valve disease).

          5. Infiltrative cardiac disease such as hemochromatosis and amyloidosis

          6. Hypertrophic cardiomyopathy

          7. Chronic pulmonary disease (FEV 1 &lt; 60% predicted)

          8. Renal failure (GFR &lt; 15 ml/min)

          9. Hemoglobin &lt; 8 g/dL

         10. BMI &gt; 40

         11. Exercise limited by angina, claudication, orthopedic, or neurological diseases.

         12. Severe liver dysfunction that is defined by an international normalized ratio &gt; 2.0,
             not caused by an anticoagulant.

         13. Current or recent treatment (within past 6 months) with erythropoietin

         14. Erythropoietin level &gt; 100 mU/ml

         15. Recent cardiac surgery (&lt; 3 months)

         16. Known iron deficiency anemia from chronic GI blood loss, uterine bleeding, or other
             chronic bleeding

         17. Planned surgery during the course of the study

         18. Significant alcohol use or illicit drug use.

         19. Patients with a known hypercoagulable state.

         20. Active hematologic disease (e.g. sickle cell anemia, thalassemia, chronic myelogenous
             leukemia) or malignancy

         21. Patients with current seizure disorder or activity

         22. Patients who are known to be pregnant

         23. History of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months
             before study entry. Prior superficial thrombophlebitis is not an exclusion criterion.

         24. History of cerebrovascular accident (CVA) within 6 months

         25. History of transient ischemic attack (TIA) within 6 months

         26. History of acute coronary syndrome (ACS), or other arterial thrombosis within 6 months
             before study entry. ACS includes unstable angina, Q wave myocardial infarction (QwMI),
             and non-Q wave myocardial infarction (NQMI).

         27. Allergy or sensitivity to human serum albumin

         28. Known hypersensitivity to mammalian cell-derived products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew S Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Cardiovascular Research Laboratory for the Elderly</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005 Apr;11(3):177-87.</citation>
    <PMID>15812744</PMID>
  </reference>
  <reference>
    <citation>Brucks S, Little WC, Chao T, Rideman RL, Upadhya B, Wesley-Farrington D, Sane DC. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol. 2004 Apr 15;93(8):1055-7.</citation>
    <PMID>15081458</PMID>
  </reference>
  <reference>
    <citation>Silverberg DS, Wexler D, Blum M, Tchebiner J, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Zubkov A, Steinbruch S, Iaina A. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol. 2002 Jul;58 Suppl 1:S37-45.</citation>
    <PMID>12227725</PMID>
  </reference>
  <reference>
    <citation>Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80.</citation>
    <PMID>11401110</PMID>
  </reference>
  <reference>
    <citation>Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003 Jan 21;107(2):294-9.</citation>
    <PMID>12538431</PMID>
  </reference>
  <reference>
    <citation>Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, Kalman J, Phillips RA, Steingart R, Brown EJ Jr, Berkowitz R, Moskowitz R, Soni A, Mancini D, Bijou R, Sehhat K, Varshneya N, Kukin M, Katz SD, Sleeper LA, Le Jemtel TH; New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004 Apr 21;43(8):1432-8.</citation>
    <PMID>15093880</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2006</study_first_submitted>
  <study_first_submitted_qc>February 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <results_first_submitted>August 17, 2015</results_first_submitted>
  <results_first_submitted_qc>May 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2016</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mathew S. Maurer</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Elderly</keyword>
  <keyword>Diastolic Dysfunction</keyword>
  <keyword>Anemia</keyword>
  <keyword>Ventricular End Diastolic Volume</keyword>
  <keyword>Aged</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erythropoietin Alpha</title>
          <description>Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
Erythropoietin alpha: Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo consists of saline injections.
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erythropoietin Alpha</title>
          <description>Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo consists of saline injections.
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" spread="11"/>
                    <measurement group_id="B2" value="74" spread="9"/>
                    <measurement group_id="B3" value="76.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular End-diastolic Volume</title>
        <description>This outcome measure is collected using a three dimensional echocardiography.</description>
        <time_frame>Baseline and 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erythropoietin Alpha</title>
            <description>Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
Erythropoietin alpha: Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo consists of saline injections.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End-diastolic Volume</title>
          <description>This outcome measure is collected using a three dimensional echocardiography.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="14"/>
                    <measurement group_id="O2" value="-4" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Erythropoietin Alpha</title>
          <description>Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo consists of saline injections.
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <description>Hospitalized</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="28"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <description>Sudden death unrelated to the treatment: Subject was vacationing and collapsed on a beach and died suddenly. No cause of death was determined.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mathew Maurer, MD, Professor of Medicine at the Columbia University Medical Center</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-9808</phone>
      <email>msm10@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

